Timothy Biggs

Mr. Timothy Biggs

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2013 in Clinical Otolaryngology
Verified
Journal Article
Closed access
PDF file
JBJ.H. Bird
J.H. Bird
TBTimothy Biggs
Timothy Biggs
CSC. Schulz
C. Schulz
NLN. Lower
N. Lower
CFC. Faris
C. Faris
CRC. Repanos
C. Repanos

27 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
RHRebecca E. Holding
Rebecca E. Holding
OLOlivia K. Lee
Olivia K. Lee
TBTimothy Biggs
Timothy Biggs
RARaymond Allan
Raymond Allan
ASAli Salamat
Ali Salamat
SPSylvia L.F. Pender
Sylvia L.F. Pender
In this study, we evaluated the antimicrobial and immunomodulatory properties of a novel bioengineered reactive oxygen species (ROS) gel that releases sustained, low concentrations of hydrogen peroxide (H2O2) upon hydration. The efficacy of the ROS gel was assessed against a multidrug-resistant clinical isolate of Staphylococcus aureus, and its effects on host defence were evaluated using human nasal epithelial cells and mast cells. The ROS gel significantly reduced Staphylococcus aureus biofilm viability while simultaneously upregulating genes involved in innate and adaptive host defence. Sustained H2O2 release enhanced the expression of antimicrobial peptides, toll-like receptor 4, and transcription factors associated with Th17 (RORC) and Th2 (GATA3) immune responses. In addition, the ROS gel modulated the expression of matrix metalloproteinases (MMP7 and MMP9) and IL10, suggesting a role in tissue remodelling and resolution of inflammation. These findings demonstrate that the ROS gel exerts dual therapeutic effects by directly inhibiting bacterial growth while modulating host transcriptional immune-associated gene responses. Harnessing ROS-based therapies may reduce reliance on conventional antibiotics and help limit the progression of antimicrobial resistance.